Abstract

Thymic epithelial tumors are rare malignancies, that may be aggressive and difficult to treat, with variable prognosis. The histopathological classification distinguishes two major tumor types: thymomas and thymic carcinomas. Autoimmune manifestations (with myasthenia gravis as the most common) are observed in nearly one third of patients at diagnosis.Assessing the resectability of the tumor represents the first stage of the therapeutic strategy, as complete resection is the most significant prognostic factor on patient survival. If complete resection seems possible upfront, surgery is the first step of the treatment, and is possibly followed by postoperative radiotherapy. For unresectable thymic tumors, pre-treatment biopsy is performed, and treatment is then based on induction chemotherapy followed by surgical resection or radiotherapy. Patients with no eligibility to focal treatment receive chemotherapy alone.Following a call of the French National Cancer Institute, a network of expert centers for the management of thymic malignancies started in 2012: RYTHMIC.1877-1203/© 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call